Nintedanib Ethanesulfonate API

Name	Nintedanib ethanesulfonate
Chinese name	乙磺酸尼达尼布
Cas Number	656247-18-6
Source	Taiwan
Qualifications	USDMF/-/-/-/-

In 2014, the FDA approved Boehringer Ingelheim's OFEV (nintedanib) for the treatment of idiopathic pulmonary fibrosis, and has previously been granted breakthrough therapy status by the FDA. Nintanib is an anti-fibrosis drug that slows down the progression of the disease by delaying the decline in lung function. It has been approved for the treatment of IPF in more than 70 countries and regions including the United States, the European Union and Japan. Nintanib is an inhibitor of multiple tyrosine kinase receptors (RTKs) and non-RTK receptors (nRTKs) with a clear targeting mechanism, and it can competitively bind to the ATP binding sites of these receptors In order to block intracellular signaling pathways, these signaling pathways play an important role in the division, metastasis and transformation of fibroblasts in the formation of interstitial lung fibrosis. Nintanib is the recommended drug in the current IPF International Guidelines and IPF China Expert Consensus. It was approved for listing in China in 2017. It is believed that the approval of this innovative drug in China will provide a powerful therapeutic weapon for Chinese respiratory doctors.

Hot Tags: nintedanib ethanesulfonate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Tippyridine Hydrochloride API, Fulvestrant API, Valganciclovir Hydrochloride API, Letrozole API, Bivalrudine API, Troxagliptin Succinate API

• Previous: Netupitant API
• Next: Tiotropium Bromide API